Impetigo – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Impetigo – Pipeline Review, H1 2020’, provides an overview of the Impetigo pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Impetigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Impetigo

– The report reviews pipeline therapeutics for Impetigo by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Impetigo therapeutics and enlists all their major and minor projects

– The report assesses Impetigo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Impetigo

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Impetigo

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Impetigo pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

FUJIFILM Toyama Chemical Co Ltd

Laboratories Ojer Pharma SL

Lipidor AB

Next Science Ltd

SutroVax Inc

Union Therapeutics AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Impetigo - Overview

Impetigo - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Impetigo - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Impetigo - Companies Involved in Therapeutics Development

FUJIFILM Toyama Chemical Co Ltd

Laboratories Ojer Pharma SL

Lipidor AB

Next Science Ltd

SutroVax Inc

Union Therapeutics AS

Impetigo - Drug Profiles

Drug for Impetigo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fusidate sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mupirocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niclosamide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ozenoxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Disrupt Bacterial Cell Wall for Impetigo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SVX-24 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Impetigo - Dormant Projects

Impetigo - Discontinued Products

Impetigo - Product Development Milestones

Featured News & Press Releases

Mar 05, 2018: Newly Approved Treatment for Impetigo to be Commercialized by Cutanea Life Sciences

Jan 08, 2018: Cipher Pharmaceuticals Announces Canadian Launch of OZANEX (ozenoxacin cream 1%), a Novel Topical Antibiotic

Dec 14, 2017: Medimetriks Pharmaceuticals Receives FDA Approval for Xepi (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo

May 08, 2017: Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%)

Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada

Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA

Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment

Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer

Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo

Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin

Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Impetigo, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Impetigo – Pipeline by FUJIFILM Toyama Chemical Co Ltd, H1 2020

Impetigo – Pipeline by Laboratories Ojer Pharma SL, H1 2020

Impetigo – Pipeline by Lipidor AB, H1 2020

Impetigo – Pipeline by Next Science Ltd, H1 2020

Impetigo – Pipeline by SutroVax Inc, H1 2020

Impetigo – Pipeline by Union Therapeutics AS, H1 2020

Impetigo – Dormant Projects, H1 2020

Impetigo – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Impetigo, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports